Skip to content


Open Access

Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation

  • Judith M Leitner1,
  • Bernd Jilma1Email author,
  • Florian B Mayr1,
  • Francesco Cardona1, 2,
  • Alexander O Spiel1,
  • Christa Firbas1,
  • Karin Rathgen3,
  • Hildegard Stähle3,
  • Uwe Schühly3 and
  • Eva U Graefe-Mody3
BMC Pharmacology20077(Suppl 2):A29

Published: 14 November 2007


PlaceboThrombinProthrombinPlatelet ActivationPartial Thromboplastin Time


BIBT 986 is a dual inhibitor of factors Xa and IIa. The aim of this study was to compare with placebo the effect of three doses of BIBT 986 on coagulation, platelet activation and inflammation.


This was a prospective, randomized, double-blind, placebo-controlled, parallel-group dose escalation trial in 48 healthy male volunteers. Participants received one of three doses of BIBT 986 or placebo intravenously together with a bolus infusion of 2 ng/kg lipopolysaccharide (LPS).


BIBT 986 dose-dependently changed global coagulation parameters and in vivo markers of thrombin generation and action: BIBT 986 doses, which prolonged activated partial thromboplastin time by 100%, completely suppressed the LPS-induced increases in prothrombin fragment, thrombin-antithrombin complexes and D-dimer, which were 6.1, 14.5, and 3.5-fold in the placebo group, respectively. BIBT 986 did not influence inflammation, fibrinolysis, or platelet activation.


BIBT 986 is a potent anticoagulant in the human endotoxemia model.

Authors’ Affiliations

Department of Clinical Pharmacology, Division of Haematology and Immunology, Medical University of Vienna, Austria
Department of Pediatrics, Division of Neonatology and Intensive Care, Medical University of Vienna, Austria
Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany


© Leitner et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd.